LYELL IMMUNOPHARMA, INC. (LYEL)
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Guidewire Announces Third Quarter Fiscal Year 2026 Financial Results
Cimpress Announces Closing of $1.1 Billion Term Loan B Maturing in 2033
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Root and Hugo Partner to Expand Access to Affordable Car Insurance for Drivers Seeking Greater Flexibility
Keel Infrastructure Announces Proposed Offering of $350 Million of Convertible Senior Notes
Concrete Pumping Holdings Reports Strong Second Quarter Fiscal Year 2026 Results
Macy’s, Inc. to Participate in 6th Annual Evercore Consumer and Retail Conference
ServiceTitan Announces Fiscal First Quarter Financial Results
Climb Global Solutions to Host Investor Day on July 7, 2026